Portal de Periódicos da CAPES

Increasing Generic Drug Use in Medicare Part D: The Role of Government

2007; Wiley; Volume: 55; Issue: 7 Linguagem: Inglês

10.1111/j.1532-5415.2007.01286.x

1532-5415

Senator Herb Kohl, William H. Shrank,

Pharmaceutical studies and practices

Journal of the American Geriatrics SocietyVolume 55, Issue 7 p. 1106-1109 Increasing Generic Drug Use in Medicare Part D: The Role of Government (See editorial comments by Dr. Richard Stefanacci on pp 1134–1136) Senator Herb Kohl (D-Wis.), Senator Herb Kohl (D-Wis.) United States Senator from Wisconsin, Majority Leader, U.S. Senate Special Committee on Aging, 2nd and C St., NE, 330 Hart Senate Office Building, United States Senate, Washington, DC 20510Search for more papers by this authorWilliam H. Shrank MD, MSHS, William H. Shrank MD, MSHS Division of Pharmacoepidemiology and Pharmacoeconoimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02120.Search for more papers by this author Senator Herb Kohl (D-Wis.), Senator Herb Kohl (D-Wis.) United States Senator from Wisconsin, Majority Leader, U.S. Senate Special Committee on Aging, 2nd and C St., NE, 330 Hart Senate Office Building, United States Senate, Washington, DC 20510Search for more papers by this authorWilliam H. Shrank MD, MSHS, William H. Shrank MD, MSHS Division of Pharmacoepidemiology and Pharmacoeconoimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02120.Search for more papers by this author First published: 28 June 2007 https://doi.org/10.1111/j.1532-5415.2007.01286.xCitations: 20 Address correspondence to William H. Shrank, MD, MSHS, Division of Pharmacoepidemiology and Pharmacoeconoimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02120. E-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 IMS Health. Available at: http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_3665_77180090,00.html Accessed February 5, 2007. 2 Heffler S, Levit K, Smith S et al. Health spending growth up in 1999; faster growth expected in the future. Health Aff (Millwood) 2001; 20: 193–203. 3 Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures-2004. Am J Health Syst Pharm 2004; 61: 145–158. 4 Congressional Budget Office. The Budget and Economic Outlook: Fiscal Years 2007 to 2016 [On-line]. Available: http://www.cbo.gov/ftpdocs/70xx/doc7027/01-26-BudgetOutlook.pdf Accessed January 30, 2007. 5 McGlynn EA, Asch SM, Adams J et al. The quality of health care delivered to adults in the United States. N Engl J Med 2003; 348: 2635–2645. 6 Shrank WH, Asch SM, Kerr EA et al. The quality of pharmacologic care for adults in the United States. Med Care 2006; 44: 936–945. 7 Higashi T, Shekelle PG, Solomon DH et al. The quality of pharmacologic care for vulnerable older patients. Ann Intern Med 2004; 140: 714–720. 8 Huskamp HA, Deverka PA, Epstein AM et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 2003; 349: 2224–2232. 9 Jaeger K. A Message from Kathleen Jaeger: It Pays to Invest in Generics. Pharmacy Times April 2006 [On-line]. Available: http://www.pharmacytimes.com/Article.cfm?Menu=1&ID=3358 Accessed May 7, 2007. 10 Haas JS, Phillips KA, Gerstenberger EP et al. Potential savings from substituting generic drugs for brand-name drugs: Medical expenditure panel survey, 1997–2000. Ann Intern Med 2005; 142: 891–897. 11 Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: Can better care cost less? JAMA 2004; 291: 1850–1856. 12 Cox E, Behm A, Mager D. 2005 Generic Drug Usage Report. Express Scripts, 2006 [On-line]. Available at: http://www.usatoday.com/news/health/2005-10-25-generic-drugs_x.htm Accessed May 7, 2007. 13 Frist WH. Health care in the 21st century. N Engl J Med 2005; 352: 267–272. 14 Kaiser Family Foundation and Health Research and Educational Trust. Employer health benefits: 2004 summary of findings. 15 Hoadley J, Hargrave E, Cubanski J et al. An In-Depth Examination of Formularies and Other Features of Medicare Drug Plans. The Henry J Kaiser Family Foundation, April 2006. 16 Federman AD, Alexander GC, Shrank WH. Simplifying the medicare prescription drug benefit for physicians and patients. Mayo Clin Proc 2006; 81: 1217–1221. 17 Avorn J. Part "D" for "defective"-the medicare drug-benefit chaos. N Engl J Med 2006; 354: 1339–1341. 18 Shrank WH, Young HN, Ettner SL et al. Do the incentives in 3-tier pharmaceutical benefit plans operate as intended? Results from a physician leadership survey. Am J Manag Care 2005; 11: 16–22. 19 Shrank WH, Fox SA, Kirk A et al. The effect of pharmacy benefit design on patient-physician communication about costs. J Gen Intern Med 2006; 21: 334–339. 20 Alexander GC, Casalino LP, Meltzer DO. Patient-physician communication about out-of-pocket costs. JAMA 2003; 290: 953–958. 21 Shrank WH, Hoang T, Ettner SL et al. The implications of choice: Prescribing generic or preferred formulary medications improves adherence to chronic medications. Arch Intern Med 2006; 166: 332–337. 22 Taira DA, Wong KS, Frech-Tamas F et al. Copayment level and compliance with antihypertensive medication: Analysis and policy implications for managed care. Am J Manag Care 2006; 12: 678–683. 23 Jha AK, Ferris TG, Donelan K et al. How common are electronic health records in the United States? A summary of the evidence. Health Aff (Millwood) 2006; 25: w496–w507. 24 Alexander GC, Casalino LP, Tseng CW et al. Barriers to patient-physician communication about out-of-pocket costs. J Gen Intern Med 2004; 19: 856–860. 25 Centers for Medicare & Medicaid Services (CMS), HHS. Medicare program; e-prescribing and the prescription drug program. Final rule. Federal Register. 2005 Nov 7;70(214):67567-95 [On-line]. Available: http://a257.g.akamaitech.net/7/257/2422/01jan20051800/edocket.access.gpo.gov/2005/pdf/05-22026.pdf Accessed January 25, 2007. 26 Kaiser Family Foundation/Harvard School of Public Health. Seniors and the Medicare Prescription Drug Benefit [On-line]. Available: URL: http://www.kff.org/kaiserpolls/upload/7604.pdf Accessed January 30, 2007. 27 Landon BE, Reschovsky JD, Blumenthal D. Physicians' views of formularies: Implications for medicare drug benefit design. Health Aff (Millwood) 2004; 23: 218–226. 28 Huskamp HA, Epstein AM, Blumenthal D. The impact of a national prescription drug formulary on prices, market share, and spending: Lessons for medicare? Health Aff (Millwood) 2003; 22: 149–158. 29 Glassman PA, Tanielian T, Harris K et al. Provider perceptions of pharmacy management: Lessons from the military health system. Med Care 2004; 42: 361–366. 30 Choudhry NK, Avorn J, Schneeweiss S et al. Should post-MI patients receive secondary prevention medications for free? An empirical policy analysis. Health Aff (Millwood) 2007; 26: 186–194. 31 Rosen AB, Hamel MB, Weinstein MC et al. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med 2005; 143: 89–99. 32 O'Malley AJ, Frank RG, Kaddis A et al. Impact of alternative interventions on changes in generic dispensing rates. Health Serv Res 2006; 41: 1876–1894. 33 Fischer MA, Schneeweiss S, Avorn J et al. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med 2004; 351: 2187–2194. 34 Rosenthal MB, Berndt ER, Donohue JM et al. Promotion of prescription drugs to consumers. N Engl J Med 2002; 346: 498–505. 35 Mott DA, Cline RR. Exploring generic drug use behavior: The role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care 2002; 40: 662–674. 36 Soumerai SB, Avorn J. Principles of educational outreach ('academic detailing') to improve clinical decision making. JAMA 1990; 263: 549–556. 37 Avorn J, Soumerai SB, Everitt DE et al. A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes. N Engl J Med 1992; 327: 168–173. 38 Van Eijk ME, Avorn J, Porsius AJ et al. Reducing prescribing of highly anticholinergic antidepressants for elderly people: Randomised trial of group versus individual academic detailing. BMJ 2001; 322: 654–657. 39 Soumerai SB, Avorn J. Economic and policy analysis of university-based drug "detailing". Med Care 1986; 24: 313–331. 40 Hensley S. Negative advertising: As drug bill soars, some doctors get an 'unsales' pitch. The Wall Street Journal, March 13, 2006, p 1. Citing Literature Volume55, Issue7July 2007Pages 1106-1109 ReferencesRelatedInformation